Clinical and translational relevance of intratumor heterogeneity.
clonal interaction
intratumor heterogeneity
single-cell technologies
treatment resistance
tumor plasticity
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
12
04
2023
revised:
03
05
2023
accepted:
05
05
2023
pmc-release:
01
09
2024
medline:
18
8
2023
pubmed:
30
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Intratumor heterogeneity (ITH) is a driver of tumor evolution and a main cause of therapeutic resistance. Despite its importance, measures of ITH are still not incorporated into clinical practice. Consequently, standard treatment is frequently ineffective for patients with heterogeneous tumors as changes to treatment regimens are made only after recurrence and disease progression. More effective combination therapies require a mechanistic understanding of ITH and ways to assess it in clinical samples. The growth of technologies enabling the spatially intact analysis of tumors at the single-cell level and the development of sophisticated preclinical models give us hope that ITH will not simply be used as a predictor of a poor outcome but will guide treatment decisions from diagnosis through treatment.
Identifiants
pubmed: 37248149
pii: S2405-8033(23)00084-5
doi: 10.1016/j.trecan.2023.05.001
pmc: PMC10524913
mid: NIHMS1899257
pii:
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
726-737Subventions
Organisme : NCI NIH HHS
ID : R35 CA197623
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests K.P. serves on the Scientific Advisory Board of Novartis, Vividion Therapeutics, Ideya Biosciences, and Scorpion Therapeutics, holds equity options in Scorpion Therapeutics, received honoraria from Astra-Zeneca, New Equilibrium Biosciences, and Roche in the past 12 months, and receives sponsored research funding from Novartis. The remaining authors have no interests to declare.
Références
Cancer Cell. 2022 Nov 14;40(11):1392-1406.e7
pubmed: 36270275
Oncologist. 2022 Mar 11;27(3):183-190
pubmed: 35274713
Science. 2021 Feb 26;371(6532):
pubmed: 33479121
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33239417
Cancer Discov. 2021 Apr;11(4):916-932
pubmed: 33811124
Nat Cancer. 2021 Jul;2(7):758-772
pubmed: 34939038
Cancer Cell. 2022 Nov 14;40(11):1423-1439.e11
pubmed: 36240778
Nat Rev Genet. 2023 Aug;24(8):494-515
pubmed: 36864178
Cell Rep. 2022 Aug 30;40(9):111283
pubmed: 36044867
Clin Med Insights Oncol. 2016 Apr 05;10(Suppl 1):31-9
pubmed: 27081325
Oncol Lett. 2019 May;17(5):4557-4565
pubmed: 30944645
Nat Rev Cancer. 2022 Nov;22(11):609-624
pubmed: 35982229
Cancer Res. 2017 Nov 1;77(21):e108-e110
pubmed: 29092952
Neuro Oncol. 2020 Aug 17;22(8):1173-1181
pubmed: 31970416
J Clin Oncol. 2019 Sep 1;37(25):2206-2216
pubmed: 31157583
N Engl J Med. 2017 Jun 1;376(22):2109-2121
pubmed: 28445112
JCO Precis Oncol. 2020 Jul 24;4:
pubmed: 32923902
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Cell. 2019 Mar 7;176(6):1325-1339.e22
pubmed: 30827679
Nat Cancer. 2022 Sep;3(9):1071-1087
pubmed: 36065066
Nat Cell Biol. 2022 Aug;24(8):1192-1201
pubmed: 35941364
Cell. 2019 Sep 19;179(1):219-235.e21
pubmed: 31522890
Nat Med. 2019 Sep;25(9):1415-1421
pubmed: 31501609
Sci Adv. 2019 Oct 09;5(10):eaax5851
pubmed: 31633026
Nat Commun. 2021 Jul 2;12(1):4098
pubmed: 34215730
J Clin Oncol. 2020 Jun 10;38(17):1951-1962
pubmed: 32330069
J Natl Cancer Inst. 2019 Aug 1;111(8):867-871
pubmed: 30888406
Nat Med. 2019 May;25(5):751-758
pubmed: 31011205
Science. 2022 Sep 9;377(6611):1180-1191
pubmed: 35981096
Arch Pathol Lab Med. 2009 Apr;133(4):611-2
pubmed: 19391661
Ann Oncol. 2019 Feb 1;30(2):211-218
pubmed: 30576421
Nat Rev Cancer. 2020 Dec;20(12):743-756
pubmed: 33033407
Endocr Relat Cancer. 2021 Jul 15;28(8):T67-T78
pubmed: 34111024
Blood. 2022 Apr 7;139(14):2198-2211
pubmed: 34864916
J Natl Cancer Inst. 2018 Jul 1;110(7):726-733
pubmed: 29361175
Am J Surg Pathol. 2020 Apr;44(4):536-544
pubmed: 31743129
Nat Med. 2019 Oct;25(10):1549-1559
pubmed: 31591606
Nat Commun. 2021 Oct 1;12(1):5775
pubmed: 34599169
Cancer Discov. 2021 Nov;11(11):2796-2811
pubmed: 34183353
Cell. 2021 Apr 15;184(8):2239-2254.e39
pubmed: 33831375
Nat Methods. 2023 Mar;20(3):363-374
pubmed: 36864196
Nature. 2023 Feb;614(7948):548-554
pubmed: 36725934
Nat Commun. 2022 Nov 4;13(1):6619
pubmed: 36333338
Curr Oncol Rep. 2021 Jan 12;23(2):15
pubmed: 33433737
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
J Clin Invest. 2020 Apr 1;130(4):1653-1668
pubmed: 32091413
Curr Opin Oncol. 2020 Nov;32(6):545-554
pubmed: 32925204
Cancer Discov. 2021 Oct;11(10):2474-2487
pubmed: 33941592
Nat Rev Cancer. 2016 Feb;16(2):110-20
pubmed: 26775620
EMBO J. 2021 Sep 15;40(18):e108389
pubmed: 34459009
Cell. 2022 Jan 20;185(2):299-310.e18
pubmed: 35063072
Nature. 2023 Feb;614(7948):555-563
pubmed: 36725935
Cell Mol Immunol. 2021 Apr;18(4):842-859
pubmed: 33139907
Cancer Res. 2023 Mar 2;83(5):667-672
pubmed: 36469010
Nat Med. 2022 Aug;28(8):1612-1618
pubmed: 35915157
Nat Med. 2018 Aug;24(8):1204-1215
pubmed: 29967352
Cancer Cell. 2020 Aug 10;38(2):229-246.e13
pubmed: 32707077
Immunity. 2022 Oct 11;55(10):1940-1952.e5
pubmed: 36223726